Phase 3 program
Amgen Refocuses Pipeline, Prioritizes Obesity Therapies Amid Strategic Cuts
Amgen, Obesity Therapies, Pipeline Cuts, Strategic Refocus, MariTide, Phase 3 Program
Vaxcyte Announces Positive Phase 1/2 Results for VAX-31, Advances to Phase 3
Vaxcyte, VAX-31, pneumococcal conjugate vaccine, Phase 1/2 study, Phase 3 program, vaccine development, bacterial diseases